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Abstract
Background: Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose
role includes assessing participant cognitive and functional performance. AD trials now investigate early stages of
the disease, when participants are not cognitively impaired. This gives rise to the question of whether study
partners or participants provide more information in these trials.
Methods: We used data from the AD Cooperative Study Prevention Instrument Project (ADCS-PI) to compare
participant and study partner predictions of the participant’s current and future cognitive state. We used the
Cognitive Function Instrument (CFI) as a measure of evaluation of the participant’s cognitive status and the
modified ADCS Preclinical Alzheimer’s Cognitive Composite (mADCS-PACC) as an objective measure of cognition.
Stratifying by cognitive status and study partner type and adjusting for other predictors of the participant’s cognitive
state, we used random forests along with estimated mean variable importance (eMVI) to assess how well each member
of the dyad can predict cognitive state at current and later visits. We also fit linear regression models at each time point
and for each scenario.
Results: Participants were better at predicting future cognitive status compared to their study partners regardless of study
partner type, though the difference between participants and partners was greatest for non-spousal dyads in the lowest-
performing quartile. Cross-sectional assessments differed substantially by dyad type. Within the lowest cognitive
performance quartile, participants having a non-spousal study partner outperformed their partners in assessing
cognition at later times. Spousal partners, in contrast, outperformed participants later in the study in predicting
current cognitive performance.
Conclusions: These results indicate that participants tend to be better at predicting future cognition compared
to their study partners regardless of the study partner type. When assessing current cognition, however, spousal
study partners perform better at later time points and non-spousal study partners do not provide as much
information regarding participant cognitive state.
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Background
Most Alzheimer’s disease (AD) clinical trials have tested
candidate therapies in patients with dementia. Interven-
tion at this stage may be too late, however, due to preva-
lent neurodegeneration [1]. Therefore, the focus has
shifted toward preclinical stages of the disease, before
overt clinical symptoms are present. AD trials at every
disease stage require the enrollment of a participant and
a study partner.
In AD dementia trials, study partners ensure informed
consent, assist with protocol compliance, and are the
source of information for a variety of trial outcome mea-
sures [2]. Not only must a participant have a study partner
who is willing and able to enroll in the trial, this study
partner should be able to provide high integrity informa-
tion about the participant’s daily life and cognition [3].
While the rationale for the study partner requirement
is clear in AD dementia trials, it is less obvious for pre-
clinical AD trials, in which participants can provide con-
sent and ensure trial compliance. Furthermore, the study
partner requirement may be a barrier to recruitment in
these trials [4]. It is therefore important to understand
the value of the information study partners provide
about the participant’s cognitive ability during the trial.
Moreover, certain types of study partners in dementia
trials may provide data of differing levels of integrity.
Previous work has shown that spousal study partners
provided more accurate information than other study
partner types when considering participants with Alzhei-
mer’s disease dementia or mild cognitive impairment
[5]. The influence of the study partner type on the ac-
curacy of information reporting has not been studied in
preclinical AD.
Here, we describe analyses of data from the Alzhei-
mer’s Disease Cooperative Study-Prevention Instrument
(ADCS-PI) project. This project set out to instruct the
design of AD prevention trials by enrolling and longitu-
dinally following older cognitively unimpaired partici-
pants and their study partners in a design that simulates
preclinical AD trials. Specifically, we investigated the in-
tegrity of participant and study partner reporting in this
setting. Because the study partner requirement is a
barrier to recruitment, we consider whether the study
partner provides additional information beyond that
provided by the participant.
Methods
Data source
The ADCS-PI design and participants have been de-
scribed elsewhere [6]. Briefly, the protocol included par-
ticipants 75 years of age or older who were fluent in
English or Spanish. Participants were required to be in
good general health and to be on stable doses of all
medications for at least 4 weeks prior to screening.
Participants were also required to be either cognitively
normal or have possible MCI, although in our study we
included only those who were cognitively normal (de-
fined by a Clinical Dementia Rating Scale [CDR]-Global
score of 0 at baseline) [7]. Participants had to be willing
and able to participate in a 4- to 5-year study and be
able to complete study procedures. They were also re-
quired to enroll with a study partner, with whom they
had contact at least twice a week and who would be able
to accompany them to all study visits. Participants were
excluded if they had medical illnesses that would prevent
their participation in the trial, alcohol or substance
abuse within the past year, major psychiatric disorders,
history of mental retardation, or were participating in a
clinical drug trial. The study partner could not have a
significant cognitive impairment, based on clinical im-
pression or history known to the investigator, or be en-
rolled in the study [6].
Participants had annual visits for 4 years after enroll-
ment into the study with a cognitive battery at each visit.
Annual cognitive batteries included the modified Mini-
Mental State Examination (mMMSE), Free and Cued Se-
lective Reminding Test (FCSRT), New York University
Paragraph Recall, Trail Making A and B, Wechsler Adult
Intelligence Scale-Revised (WAIS-R) Digit Symbol Sub-
stitution Test, Boston Naming Test (10-item version),
verbal fluency test (animals), and Geriatric Depression
Scale (GDS). At the baseline visit, participants were ran-
domized to take new experimental assessments either at
home or in the clinic. All study participants provided
written informed consent.
We used the participant and study partner versions of
the Mail-In Cognitive Function Screening Instrument,
which we refer to simply as the Cognitive Function In-
strument (CFI), to compare the information provided by
each member of the dyad. The CFI includes 2 sets of
questions, 1 each for the participant and the study part-
ner. Each set consists of 14 questions that ask about
functional decline in the past year. The study partner
and participant were asked to complete these questions
independently, but the study partner was allowed to con-
sult other people as long as it was not the participant.
Questions were scored as “yes” (1 point), “no” (0 points),
and “maybe” (0.5 points). The total score was calculated as
the sum of the answers to each of the 14 questions, giving
a possible range of 0 to 14. Several questions regarding
driving, finances, and work performance had “not appli-
cable” as another possible answer [8, 9]. For questions
answered as “not applicable,” we imputed the mean of the
available responses.
We used the modified Preclinical Alzheimer’s Cogni-
tive Composite (mADCS-PACC) [9, 10] as an objective
measure of cognition. This composite score was a com-
bination of the original mADCS-PACC and the PACC-5
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and included total recall from the Free and Cued Select-
ive Reminding Test (FCSRT), New York University Para-
graph Recall, Digit Symbol Substitution Test from the
Wechsler Adult Intelligence Scale-Revised, mMMSE,
and the animal fluency test [10, 11]. For each compo-
nent, we calculated a z-score using the baseline sample
mean and standard deviation for all participants with a
CDR-Global score of 0. The z-scores across all compo-
nents were averaged, and this value was used as the out-
come, with lower scores indicating poorer cognition. If
any components were missing, the outcome was calcu-
lated using the mean of the available components.
Analyses
We used random forests to assess how well each mem-
ber of the dyad predicted participants’ cognitive state at
current and later visits. We used mADCS-PACC score
as the response and included the baseline scores for
CDR Sum of Boxes (CDR-SB) and participant and study
partner CFI along with ethnicity, gender, age, education,
and history of cardiovascular disease. Ten observations
(0.7%) were missing 1 component of the mADCS-PACC,
and 2 observations (0.2%) were missing 3 components.
We used the GRF package in R to generate random for-
ests. To account for variability stemming from the ge-
neration of the random forests, we created 100 random
forests using the same data with different random seeds
and obtained a variable importance measure each time.
The variable importance measure used was a weighted
sum of the number of times variables were selected for
splitting, with splits higher in the tree having larger
weight. We calculated the mean of the variable import-
ance estimates, which we refer to as the estimated mean
variable importance (eMVI), along with corresponding
95% uncertainty bounds (UB), which were obtained
using the 2.5th and 97.5th percentiles of the 100 ob-
served variable importance values. To investigate
whether participant cognitive performance affected the
observed relationships, we stratified participants using
quartiles of the mADCS-PACC at baseline. The lowest
quartile included participants with the poorest cognitive
performance while the highest quartile included partici-
pants with the highest cognitive performance. To quan-
tify differences in predictive performance between study
partner types, we further stratified participants into
spousal and non-spousal dyads. We also fit linear regres-
sion models for each stratum adjusting for the same var-
iables that were used to generate the random forest
results. To investigate how well current participant and
study partner CFI scores predict current cognitive state,
we repeated this procedure for each of the 4 years using
cross-sectional scores for the mADCS-PACC, CFI, and
CDR-SB.
Fifteen observations were excluded from the baseline
analysis because either baseline participant or study
partner CFI was missing. Seventy-two observations were
excluded from the cross-sectional analysis because
cross-sectional participant or study partner CFI was
missing. Participants who dropped out were asked to re-
turn for a final visit. These visits were included in our
analyses as the closest annual visit. Two treatment dis-
continuation visits were removed from our analysis be-
cause the participants already had a visit for the year
closest to the treatment discontinuation. Three partici-
pants who were missing mADCS-PACC at baseline were
also excluded from the cross-sectional analysis.
Results
Description of the sample
Our analyses included 450 participants, 189 who had a
spousal study partner and 261 who had a non-spousal
study partner (Table 1). Participants in the dyad groups
were similar in age, education, mMMSE score, and
CDR-SB score. The non-spousal group included more
females (75.9% compared to 36.5%) and more non-
Caucasians (30.3% compared to 8.5%) than did the spou-
sal group. In both groups, participants rated their cogni-
tion worse than their partners did, though this
difference was larger among non-spousal compared to
spousal dyads. Study partners in the non-spousal group
were younger and more often females, compared to the
spousal group.
Prospective prediction of future mADCS-PACC score
We first examined whether baseline CFI predicted
mADCS-PACC scores at subsequent time points. We
found that the eMVI for participant CFI was higher than
that for study partner CFI (Fig. 1a). In the first year, the
eMVI for participant CFI was 0.25 (95% UB: 0.23, 0.26)
and that of the study partner was 0.07 (95% UB: 0.06,
0.07). This remained true when we stratified by study
partner type (spousal vs. non-spousal), as seen in Fig. 1b.
For example, the eMVI among spousal dyads for pre-
dicting cognitive performance after the first year was
0.25 (95% UB: 0.24, 0.27) for participant CFI and 0.19
(95% UB: 0.18, 0.21) for study partner CFI. Among non-
spousal dyads, the eMVI was 0.23 (95% UB: 0.22, 0.24)
and 0.05 (95% UB: 0.05, 0.06) for participant and study
partner CFI, respectively. When we stratified by quartiles
of cognitive performance (defined by mADCS-PACC
scores at baseline), we found that among the poorest-
performing participants with spousal study partners, the
participant and study partner performed similarly
(Fig. 1c). Among non-spousal dyads, the eMVI was
higher for participant CFI all 4 years and the difference
between participant and study partner CFI increased
over time. In year 1, for example, the eMVI was 0.20
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(95% UB: 0.19, 0.21) for participant CFI and 0.13 (95%
UB: 0.12, 0.14) for study partner CFI. In year 4, the
eMVI was 0.41 (95% UB: 0.39, 0.45) and 0.08 (95% UB:
0.07, 0.12) for participant and study partner CFI,
respectively (Fig. 1c). The coefficient estimates also in-
creased in magnitude over time. In the other quartiles,
we found that the eMVI for participant CFI was usually
higher than that of the study partner CFI (see
Additional file 1).
Cross-sectional prediction of current mADCS-PACC score
We also examined the performance of participant and
study partner CFI for predicting current mADCS-PACC
scores. There were no clear trends between participant and
study partner CFI. In years 1, 2, and 4, the eMVI was larger
for the participant than for the study partner CFI while in
year 3, the eMVI was higher for the study partner CFI
(Fig. 2a). When we stratified by study partner type, we ob-
served differences between the study partner and partici-
pant. As seen in Fig. 2b, among spousal dyads, the eMVI
for participant CFI was higher than the study partner eMVI
in the first 2 years; in years 3 and 4, the eMVI was higher
for study partners. Among non-spousal dyads, the eMVI
for participant CFI was higher than that for study partner
CFI all 4 years, and the largest difference was observed in
year 4 (Fig. 2b). In year 4, the participant CFI was 0.41 (95%
UB: 0.40, 0.43) while that of the study partner, CFI was 0.14
(95% UB: 0.13, 0.16). Figure 2c illustrates the eMVIs for
participants and study partners in the poorest-performing
quartile over the course of the study, again defined based
Table 1 Baseline description of ADCS-PI participants with a CD-Global score of 0 at baseline and at least 1 mADCS-PACC score and
participant and study partner CFI available after baseline
Spousal dyads (N = 189) Non-spousal dyads (N = 261)
Participant characteristics
Age, mean (SD) 78.92 (3.37) 79.77 (3.75)
Years of education, mean (SD) 15.59 (2.79) 14.80 (3.01)
Female sex, n (%) 69 (36.51) 198 (75.86)
Caucasian race, n (%) 173 (91.53) 182 (69.73)
mMMSE, mean (SD) 96.25 (2.97) 95.43 (3.75)
CDR-SB, mean (SD) 0.07 (0.18) 0.10 (0.20)
Participant CFI, mean (SD) 1.81 (1.88) 2.16 (2.04)
History of cardiovascular disease, n (%) 119 (62.96) 178 (68.20)
mADCS-PACC, mean (SD) 0.06 (0.62) 0.01 (0.70)
Study partner characteristics
Study partner age, mean (SD) 76.08 (6.45) 64.08 (14.88)
Study partner female sex, n (%) 120 (63.49) 217 (83.14)
Study partner CFI, mean (SD) 1.10 (1.74) 1.04 (1.58)
Total contact time (days), mean (SD) 7.00 (0.00) 4.58 (2.04)
Fig. 1 Forest plots presenting the estimated mean variable importance and 95% uncertainty bounds marginally (a), stratified by study partner
type (b), and for the lowest (poorest performing) quartile of baseline mADCS-PACC (c) using baseline participant and study partner CFI
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on the mADCS-PACC scores at baseline. As with the full
sample, in spousal dyads, the participant performed better
during the first 2 years while the study partner performed
better during the last 2 years. Among non-spousal dyads,
the study partner and participant performed similarly
during the first 2 years. In years 3 and 4, the eMVI for par-
ticipant CFI was higher than that for study partner CFI.
The results for the other quartiles can be found in
Additional file 1.
Discussion
In this study, we investigated whether participant or
study partner report was better at predicting cognitive
performance in a study population intended to model
AD prevention trial samples. We focused on individuals
who were at greatest risk to show a cognitive decline—
those with the lowest performance at baseline—since the
source dataset did not include AD biomarkers, which
are used to enrich preclinical AD trials and ensure statis-
tical power [1]. We found that participants were better
at predicting future cognitive performance (Fig. 1c) but
that among spousal dyads, partners increasingly outper-
formed participants in predicting cognitive performance
cross-sectionally over the course of study (Fig. 2c). This
observation, which is similar to previous studies [12, 13],
including previous analyses of this dataset [9, 14], sug-
gests that knowledgeable informants may play an in-
creasingly important role in identifying and quantifying
cognitive changes over time in AD prevention trial
participants.
This paper has several unique strengths. Our results are
based on a large sample (n = 450), and we used a flexible
prediction model to consider the participant and study
partner performance. The model included study partner
and participant CFI simultaneously, allowing us to com-
pare the importance of each source of information. Our
model also included other factors likely to predict CFI. By
fitting linear models, we were also able to assess the
magnitude and directionality of the relationships.
Another important strength of the current study is that
we examined study partner characteristics as potential
effect modifiers. When we stratified our analyses by dyad
type, we found that among those with the poorest cogni-
tion, spousal study partners performed similarly to the
participants in predicting mADCS-PACC scores, while
participants with non-spousal study partners substantially
outperformed their partners (Fig. 1c). When predicting
the current cognitive state, we found no clear trends be-
tween the participant and study partner performance
overall. But when we stratified our analyses by study part-
ner type, we found that spousal study partners performed
better than participants at later times. Participants without
a spouse outperformed their partners in predicting cogni-
tive performance, even at later time points (Fig. 2b, c).
Though these results are novel in relation to assessing
study partner performance in AD prevention/preclinical
AD trials, they are supported by observations in dementia
and MCI. For example, Ready and colleagues showed that
study partners who live with impaired participants (demen-
tia and MCI) provide subjective reports that most strongly
correlated with participant performance on a wordlist
memory task, and these partners were most often spouses
[5]. Non-spousal dyads are also at increased risk for drop-
out and partner replacement [15, 16], both of which can
increase trial variance. Determining whether something
specific to the nature of the relationship drives this effect or
if it is some other factor such as residence status or the
type, quantity, or quality of interactions between dyad
members will require further research. Future research
should also focus on methods to improve the integrity of
the data provided by non-spousal partners, especially since
they are underrepresented in trials and could expedite AD
research if enrolled with greater frequency [17].
Our results indicate that all participants, regardless of
their partner type, provide information about their fu-
ture cognition that is at least as accurate as the informa-
tion provided by partners. In most cases, participants
better predict their future performance than do their
Fig. 2 Forest plots presenting the estimated mean variable importance and 95% uncertainty bounds marginally (a), stratified by study partner
type (b), and for the lowest (poorest performing) quartile of baseline mADCS-PACC (c) using cross-sectional participant and study partner CFI
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partners. This observation may be important when
considering optimal means to recruit to AD prevention
trials, for example, from large registries. Depending on the
goals and design of the specific trial, participant or partner
reports of cognitive performance may be prioritized. It may
also be important to the design of registries, since securing
dyadic participation in registries necessitates added burden
and cost. Nonetheless, having both reports, along with
objective measures of cognitive performance, enables co-
ordinated approaches that likely yield higher precision [18].
Overall, these results support the continued practice
of dyadic enrollment in prevention/preclinical AD
trials for the value partners bring to assessing cogni-
tive performance. Study partners may also help partic-
ipants deal with anxiety and distress related to AD
risk disclosure and reduce study dropout by providing
support networks for participants. Enrolling with a study
partner may also allow the partner to become a trusted
advocate who can facilitate planning and knows how the
participant would like to be cared for in the case that they
develop dementia [19]. Nevertheless, our results also
indicate that careful consideration for the requirements of
this role may be needed to optimize data integrity.
Limitations
Several limitations of this study should be noted. Pre-
clinical AD trials now enroll based on genetic and bio-
marker criteria as a strategy to identify participants at
greatest risk for disease, to enrich for those most likely
to benefit from therapy, and to improve statistical power
[1, 20]. Although we did not have these variables to in-
clude in our analyses, we stratified by cognitive perform-
ance in an effort to replicate their purpose. We used a
modified version of the mADCS-PACC to quantify cog-
nition and CFI to assess participant and study partner
views about the participant’s cognitive state. It is unclear
whether our results are generalizable to other available
tools, either for assessing participant cognitive perform-
ance [21] or subjective assessment of that performance
[22]. In an accompanying paper by our group, however,
we observed that these results generalize to the measure-
ment of subjective assessments with the Everyday Cogni-
tion (ECog) scale and objective assessment with the
Alzheimer’s Disease Assessment Scale-Cognitive-13
(ADAS-Cog-13) [23]. Finally, like actual interventional
trials, the ADCS PI was subject to sample bias such as
the inclusion of highly educated participants.
Conclusions
Our analyses show that participants at risk for cognitive
impairment with non-spousal study partners tend to be
better at predicting their future cognitive performance
than are their study partners. Spousal study partners,
however, outperform participants in recognizing current
cognitive performance at later time points. Therefore,
study partner characteristics, in this study assessed based
on the relationship between the partner and the partici-
pant, seem to modify the relationship between informant
report and objective trial data. Thus, these results sug-
gest that the study partner role may be important to the
integrity of preclinical AD trial data but warrant further
research to investigate ideal informant characteristics
and interventions to increase the integrity of the data
they provide.
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Additional file 1: Table S1. Coefficient estimates for participant and
study partner baseline CFI scores based on linear models in which the
response is mADCS-PACC at each year and we adjust for each year’s
scores of participant and study partner CFI, CDRSB, ethnicity, gender, age,
education, and history of cardiovascular disease. Table S2. Coefficient
estimates for participant and study partner CFI based on linear models in
which the response is mADCS-PACC at each year and we adjust for
participant and study partner CFI and CDRSB at each year along with
ethnicity, gender, age, education, and history of cardiovascular disease.
Table S3. Coefficient estimates corresponding to the linear models with
baseline CFI. Table S4. Estimated mean variable importance (eMVI) and
95% UB for random forests with baseline CFI measures. Table S5.
Coefficient estimates corresponding to the linear models with cross-
sectional CFI. Table S6. Estimated mean variable importance (eMVI)
and 95% UB for random forests with cross-sectional CFI measures.
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